Tirzepatide: Dual GIP/GLP-1 Agonist With Superior Weight Loss Data
Tirzepatide (Mounjaro / Zepbound): The First-in-Class Dual GIP/GLP-1 Receptor Agonist With FDA-Approved T2DM, Obesity, and Sleep Apnea Indications and Superior Weight Loss to Semaglutide in 2025 SURMOUNT-5 By Medical Team of Generic Peptides Tirzepatide (LY32…











